Monday, 24 June 2019｜Source：CHINA CHAMBER OF COMMERCEFOR IMPORT&EXPORT OF MEDICINES &HEALTH PRODUCTS｜Author：
On June 18, the 19th CPhI China, organized by Informa Markets and CCCMHPIE, co-organized by Sinoexpo Informa Markets, and other exhibitions such as P-MEC China 2019, ICSE China 2019, NEX China 2019, Innopack China 2019, and LABWorld China 2019 is staged concurrently at the Shanghai New International Expo Center (SNIEC).
The exhibition area this year exceeds 200,000 square meters for the first time, with more than 3,200 domestic and foreign exhibitors and over 70,000 visitors from 120 countries and regions to join the great event of the pharmaceutical industry. As the vane of the international pharmaceutical industry, this exhibition will be based on transformation and upgrading to help companies to write a new chapter in pharmacy and open up a new pattern of international pharmaceutical market.
Mr. Zhou Hui, President of CCCMHPIE, and Mr. Adam Andersen，Group Director for the Informa Markets Pharma portfolio delivered opening speeches on behalf of exhibition organizers.
Mr. Zhou expresses that after years’ of hard work, China becomes an important role in international division, adds depth and width. As major producer, China excels in APIs and herbal extracts.
We are now under the shadow of trade frictions with multiple uncertainties. Pharmaceutical industry value chain is undergoing profound changes. Under this circumstance, it is a strategic question for us to cope with, to actively involve, and to reshape the value chain. And it has always been the mission of our show.
He says, as world-leading platform for goods trade and information exchange, the CPhI brand appeal has become the first choice for upstream and downstream companies.
Adam Andersen says, growing rapidly, while simultaneously expanding its technological capabilities and knowledge, the Chinese pharma market is reaping the rewards of the significant reformation efforts by the National Medical Products Administration. Testament to this improvement is the substantial upturn in perception of China across pharma – with exclusive CPhI Annual Report data highlighting a 9.64% increase in its reputation in the last year alone.
This is reflected in how dynamic and positive the market fundamentals are, to highlight some of them: More international opportunities are continuing to diversify, with many international companies here looking for domestic partners-this is highlighted by the more than 120 countries represented at CPhI China this year; the National Medical Products Administration is making considerable efforts to harmonise with global standards; the biotech industry continues to grow, with new biologics facilities and a rapidly developing supplier base; generics and ingredients are undergoing sustained robust growth-with patients here quickly increasing their use of drugs and spending on healthcare; The region is also emerging as a major global finished formulations hub, with pharmaceutical machinery supporting ever increasing manufacturing capabilities.
Mr. Zhou Hui, Ms. Margaret Ma Connolly, CEO of Informa Markets Asia, Mr. Zhang Wei, Secretary General of Chinese Pharmacopoeia Commission, Mr. Adam Andersen，Mr. Xu Xingfeng, Deputy Special Commissioner of Shanghai Sp ecial Commissioner’s Office of Ministry of Commerce of China, Ms. Hanna Arayaselassie Zemichael, Deputy Commissioner of Ethiopian Investment Commission (EIC), Ms. Alison Jenkins, Senior Adviser，South South Cooperation and Partnerships of UNICEF office for China, Mr. Ichiro FUJIKAWA, Chairman of Japan Pharmaceutical Traders' Association, Mr. Oh Jang Suk, Chairman of Korea Pharmaceutical Traders Association, Dr. Gabriel Giancaspro, Vice President of Science—Dietary Supplements and Herbal Medicines, USP, Mrs. Caroline Larsen Le Tarnec，Head of Public Relations & Documentation Division，European Directorate for the Quality of Medicines & HealthCare (EDQM, Council of Europe), Mr. Zhang Hongxiang, Executive Deputy Secretary-General, Chinese Society of Biotechnology, Mr. Jiang Xuejun, Chief，office for Asia and the Pacific，International Trade Centre attend the opening ceremony and cut the ribbon for the exhibition.
Distinguished guests from Chinese Pharmaceutical Association, United Natural Products Alliance, Medical Products Administrative Departments, Commerce Departments, Trade Promotion Organizations, and Industrial Parks at provincial or municipal level also attend the opening ceremony.
This exhibition has national pavilions for exhibitors from India, South Korea, Turkey, Poland, Russia, and etc. This year, BioPh China, which has been held for seven consecutive years, has been upgraded to “bioLIVE China”. BioLIVE China 2019 focuses on life sciences, biotechnology and innovative products, and the guidance to biomedical technology innovation and industrial development, and has created a grand event for the leading industrial chain of Asian pharmaceutical industries by joining hands with CPhI China 2019. In addition to professional and exciting exhibitions, bioLIVE China 2019 has also organized more than 100 conferences and forums in the three days, providing high-end, professional, open and information-shared learning and communication platforms for pharmaceutical professionals at home and abroad, and promoting the going global of Chinese brands.
